#Neuroscience
Brain-targeted peptide work: nootropics, neuroprotection, stroke recovery.
GLP-1 drugs in IIH: what research shows
A 2026 Headache meta-analysis finds GLP-1 receptor agonists reduce intracranial pressure and headache days in IIH. What the data shows.
Selank and Semax: Should You Combine Them?
Selank has real generalized anxiety disorder trial data. Semax's focus reputation does not, and no study has combined the two.
Peptide cycles per year: no number exists
Cycle lengths come from a few small trials. Cycle counts come from nowhere, because no study has tested repeating a peptide course across a year.
Semaglutide and reward: what research shows
GLP-1 receptors sit inside the brain's dopamine reward circuit. Early trials suggest semaglutide may reduce craving well beyond food.
Semax and alcohol cravings: the evidence
No human study shows that Semax reduces alcohol cravings, and one quoted animal result cannot answer a personal safety question.
ACTH-fragment nootropics: what we know
Semax, Org 2766 and ACTH(4-10) itself come from one hormone. Here is what the class evidence shows in humans, and where it runs out.
Semax and Selank together: the evidence
Semax and Selank are Russian nootropic peptides with small, mostly Russian-language trial records. No published study has given both to the same person.
Thymosin β4 and pyroptosis in microglia
A July 2026 cell-culture study reports that thymosin beta-4 lowers pyroptosis markers in BV2 microglia. Here is what that does and does not show.
Semaglutide alters NAc oscillations in mice
Molecular Brain (July 2026) finds semaglutide changes nucleus accumbens oscillations and reward behaviour in healthy mice, not just in metabolic disease models.
GLP-1 neuro research: what 20 years shows
A 2026 bibliometric analysis mapped 1,202 publications on GLP-1 receptor agonists in neurodegenerative disease from 2006 to 2025.
What Penn Medicine's 'food noise' case study actually showed
Casey Halpern's Nature Medicine case study recorded nucleus-accumbens activity in a single patient on tirzepatide. Activity was suppressed early, then returned at 5 months alongside renewed cravings.